Brendan O’Malley is Vice President, Head of Legal & IP and Corporate Secretary at Abeona Therapeutics, a fully-integrated gene and cell therapy company focusing on the treatment of rare childhood genetic diseases.
Brendan joined Abeona in 2019 as Chief IP Counsel and still fulfills that role as part of his overall responsibilities, managing the company’s patent and trademark portfolios and protecting the company’s trade secrets.
Prior to joining Abeona, Brendan was a partner at Fitzpatrick Cella Harper & Scinto, where he started his career as a summer associate in 2006, and then at Venable LLP, which merged with Fitzpatrick in 2018. While at Fitzpatrick and Venable, he litigated a wide variety of biopharmaceutical patent cases in the United States District Courts, at the Federal Circuit, and before the U.S. Patent and Trademark Office, negotiated numerous settlement and license agreements, and provided many patent opinions in connection with M&A due diligence in the biotech space.
While attending law school at Benjamin N. Cardozo School of Law, Brendan served as a judicial intern to Judge William H. Pauley in the U.S. District Court for the Southern District of New York.
Before law school, he earned a Ph.D. in Molecular Biology & Microbiology from Tufts University School of Medicine, where he studied the role of protein-protein interactions in hepatitis virus assembly, and a B.S. degree magna cum laude from the University of Massachusetts Dartmouth.